Eton Pharmaceuticals, Inc.

Total Valuation

Eton Pharmaceuticals, Inc. carries a market capitalization of 866.15M, placing it among publicly traded companies globally. Its enterprise value stands at 677.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Eton Pharmaceuticals, Inc. currently has 27.36M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 7.67, and the price-to-book ratio stands at -6.01.

Enterprise Valuation

On an enterprise value basis, Eton Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 109.31 and an EV/FCF ratio of 20.11. The EV/Sales ratio of 7.80 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 332.32 provides insight into valuation relative to core operating earnings.

Financial Position

Eton Pharmaceuticals, Inc. maintains a current ratio of 1.21, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 101.87, indicating elevated leverage, while an interest coverage ratio of 2.50 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Eton Pharmaceuticals, Inc. has paid -11,000.00 in income taxes, reflecting an effective tax rate of 1.27.

Stock Price Statistics

Eton Pharmaceuticals, Inc.'s stock has gained approximately 123.14749% over the past 52 weeks. The 50-day moving average sits at 28.39, while the 200-day moving average is 20.41.

Income Statement

Over the trailing twelve months, Eton Pharmaceuticals, Inc. generated 86.93M in revenue and converted that into -1.47M in net income, yielding earnings per share of -0.05. EBITDA reached 6.20M, while operating income came in at 2.04M.

Balance Sheet

Eton Pharmaceuticals, Inc. holds 19.66M in cash and equivalents against 31.19M in total debt, resulting in a net debt position of 11.09M. Total book value stands at -110.91M, with working capital of 9.07M providing operational flexibility.

Cash Flow

Eton Pharmaceuticals, Inc. produced 15.84M in operating cash flow over the past twelve months. After subtracting -15.41M in capital expenditures, free cash flow totaled 431,000.00 - equivalent to 0.02 per share.

Margins

Eton Pharmaceuticals, Inc. operates with a gross margin of 54.77, reflecting its pricing power and cost economics. The operating margin of 2.35 and net profit margin of -1.70 provide insight into operational efficiency.

Dividends & Yields

Scores

Eton Pharmaceuticals, Inc. posts an Altman Z-Score of 5.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.